Focal Segmental Glomerulosclerosis Clinical Trial
— TRANSLATEOfficial title:
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"
Verified date | January 2018 |
Source | University Health Network, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with Focal Segmental Glomerulosclerosis (FSGS) constitute an increasing proportion of the total glomerulonephritis (GN) patient cohort in North America while FSGS is a risk factor for end stage renal failure. Current non-immunological FSGS therapies include the use of angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), to reduce intraglomerular hypertension. Unfortunately, these agents lead to incomplete renal protection. The aim of the current study is to determine whether the addition of novel sodium glucose cotransport-2 inhibitors (SGLT2i) to standard of care leads to reduced intraglomerular pressure and suppression of proteinuria. We hypothesize that combination therapy of SGLT2i drugs and conventional RAASi results in additive renal protective effects in FSGS patients. A further goal is to examine mechanisms of SGLT2 inhibition by measuring renal hemodynamic function and sodium handling. Kidney function will be assessed in FSGS patients before and after an 8 week treatment with SGLT2i dapagliflozin.
Status | Completed |
Enrollment | 10 |
Est. completion date | April 24, 2017 |
Est. primary completion date | April 24, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female subjects diagnosed with FSGS =1 month prior to informed consent - eGFR=45 ml/min/1.73m2 - Age 18 years or greater - No history of diabetes - Body Mass Index (BMI) 18.5 - 45.0 kg/ m2 - Blood pressure = 100/60 at screening - Stable therapy with either an ACEi or angiotensin II receptor blocker or direct renin inhibitor for > 1 month - >30 mg/day and <6 g/day of proteinuria unless the patient is not a candidate for immunosuppressive therapy Exclusion Criteria: - Leukocyte and/or nitrite positive urinalysis that is untreated; - History of organ transplantation, cancer, liver disease; - Bariatric surgery or other gastrointestinal surgeries that induce chronic malabsorption within the past two years; - Current treatment with systemic corticosteroids, calcineurin inhibitors, or other immunosuppressant medications; - Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells; - Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practising an acceptable method of birth control; - Participation in another therapeutic trial with an investigational drug within 30 days prior to informed consent; - Alcohol or drug abuse within three months prior to informed consent that would interfere with trial participation or any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement; - Liver disease, defined by serum levels of alanine transaminase, aspartate transaminase, or alkaline phosphatase >3 x upper limit of normal as determined during screening; - Cardiac, lung or peripheral vascular disease or stroke; - Pancreas, pancreatic islet cells or renal transplant recipient; - Medical history of cancer or treatment for cancer in the last five years prior to screening; - History of allergy or angioedema with RAAS inhibitor exposure; - Kidney disease due primarily to another condition aside from FSGS; |
Country | Name | City | State |
---|---|---|---|
Canada | Renal Physiology Laboratory, University Health Network | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto | AstraZeneca, Toronto General Hospital, University of Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change in Glomerular Filtration Rate (GFR) After an 8 week treatment with dapagliflozin | Glomerular Filtration Rate (GFR, based on plasma inulin clearance) will be measured at baseline and after 8 weeks of treatment. | Before and after an 8 week treatment with dapagliflozin | |
Secondary | The change in Effective Renal Plasma Flow (ERPF) After an 8 week treatment with dapagliflozin | Effective Renal Plasma Flow (ERPF, based on paraaminohippurate plasma clearance) will be measured at baseline and after 8 weeks of treatment. | Before and after an 8 week treatment with dapagliflozin | |
Secondary | The change in Blood Pressure After an 8 week treatment with dapagliflozin | Before and after 8 weeks of treatment with dapagliflozin | ||
Secondary | The change in albuminuria after 8 weeks of treatment with dapagliflozin | Before and after 8 weeks of treatment with dapagliflozin | ||
Secondary | The change in urinary vasoactive mediators after 8 weeks of treatment with dapagliflozin | Before and after 8 weeks of treatment with dapagliflozin |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Not yet recruiting |
NCT00956059 -
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
|
N/A | |
Recruiting |
NCT05588063 -
taVNS for FRNS in Children
|
N/A | |
Recruiting |
NCT05583942 -
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
|
N/A | |
Completed |
NCT04369183 -
Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
|
||
Recruiting |
NCT02896270 -
Valproic Acid for Idiopathic Nephrotic Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT01113385 -
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
|
N/A | |
Terminated |
NCT00883636 -
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
|
N/A | |
Completed |
NCT04009668 -
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
|
Phase 2 | |
Terminated |
NCT03703908 -
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
|
Phase 2 | |
Completed |
NCT03649152 -
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
|
Phase 2 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Completed |
NCT00255398 -
Kidney Disease Biomarkers
|
||
Terminated |
NCT05441826 -
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
|
Phase 2 | |
Recruiting |
NCT02235857 -
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
|
N/A | |
Recruiting |
NCT05942625 -
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT02382874 -
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
|
Phase 1 | |
Completed |
NCT00464321 -
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
|
Phase 1 | |
Completed |
NCT03536754 -
A Study of CCX140-B in Subjects With FSGS
|
Phase 2 | |
Recruiting |
NCT03929887 -
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
|